Evidence map›Paper›PMID 41002593›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Pulmonary Embolism Associated with Olaparib in

Shuhei Ishii, Shigekatsu Maekawa, Fumiko Amano, Daichi Kikuchi, Daiki Ikarashi, Renpei Kato, Mitsugu Kanehira, Ryo Takata, Jun Sugimura, Wataru Obara

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuhei IshiiDepartment of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan.ORCID 0000-0003-3840-2104
Shigekatsu MaekawaDepartment of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan.ORCID 0000-0003-4620-2831
Fumiko AmanoDepartment of Urology, Iwate Prefectural Kamaishi Hospital, 10-483-6 Kasshi, Kamaishi 026-8550, Iwate, Japan.
Daichi KikuchiDepartment of Urology, Iwate Prefectural Kamaishi Hospital, 10-483-6 Kasshi, Kamaishi 026-8550, Iwate, Japan.
Daiki IkarashiDepartment of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan.
Renpei KatoDepartment of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan.
Mitsugu KanehiraDepartment of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan.
Ryo TakataDepartment of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan.
Jun SugimuraDepartment of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan.
Wataru ObaraDepartment of Urology, Iwate Medical University, 2-1-1 Idai-dori, Yahaba, Shiwa 028-3695, Iwate, Japan.ORCID 0000-0003-2720-9640

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor approved for treating metastatic castration-resistant prostate cancer (mCRPC) with

Indexed as

BRCA2 ProteinPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsProstatic Neoplasms, Castration-ResistantPulmonary EmbolismAgedHumansMaleMutationBRCA2 ProteinBRCA2 protein, humanolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsanticoagulationD-dimermCRPColaparibpulmonary embolism

Identifiers

PMID41002593
PMCPMC12468111

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.